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Abstract: Th e rare occurrence of the fallopian tubes cancer allows to assert that the experience of even 
a small number of observations has a undoubted scientifi c and practical interest. Nowadays this type of 
neoplasia occurs more oft en in practical oncogynecology and is the primary source of serous ovarian and 
peritoneal tumors. Th e determination of tissue receptor status of primary fallopian tube cancer (ER, PR, 
Ki-67, HER2 / neu) will verify the degree of biological malignancy and predict the course of disease and 
suggest appropriate methods of treatment.
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Introduction
Despite signifi cant progress in the study of malignant tumors, the primary cancer 
of the fallopian tubes (PFTC) is not fully studied yet. According to diff erent authors 
its incidence accounts from 0.14% to 1.8% of all female genital malignancies [1, 2]. 
Th e causes of the fallopian tube cancer are still not clearly determined in modern 
gynecology. In literature there is some information that the patients with BRCA1 or 
BRCA 2 gene mutations are more vulnerable to this disease [3, 4]. In case of malignant 
tube-ovarian tumors the localization of primary neoplastic process is oft en diffi  cult to 
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determine thus in most cases the fallopian tubes carcinoma is mistakenly diagnosed 
as ovarian cancer. Taking into account this fact, it can be assumed that this type of 
neoplasia occurs more oft en in clinical practice. Aft er detailed study of infundibulum 
parts of the fallopian tubes R. Wilcox concluded that the ratio of PFTC of all tumors 
of the uterine appendages is 15% (p <0.001) but not 2.3% as it was previously 
determined [5]. Th e PFTC is diagnosed if it damages the fallopian tube. Th is process 
must be dominated over the malignant process in the uterine and ovary or when its 
histologic structure is heterogeneous [6, 7]. Over the last decade it was proved that 
the fallopian tubes are the primary source of serous ovarian and peritoneal tumors 
[8]. Despite the ongoing discussions on the origin of ovarian, peritoneal and fallopian 
tubes cancer, these tumors are still classifi ed as independent nosologic units according 
to international classifi cations [9]. Overall 5-year survival rate with PFTC is only 35% 
due to the rapid lymphatic spreading of the cancer [10].
The modern oncomorphology is in search of the criteria that will allow to 
verify the degree of biological malignancy and to predict the course of the disease 
with maximum objectivity. Th e study of molecular markers will allow to provide 
the adequate treatment of the patients with advanced processes and to improve the 
assessment of vulnerability to certain therapies. Steroid hormone receptors were 
among the fi rst indicators implemented into practice and classifi ed as cellular markers, 
which are determined in tumor tissue and characterize its biological properties and 
“behavior” [11]. Thus, the breast tumor with positive estrogen and progesterone 
receptor status has better survival rates than with negative receptor status and is one of 
the most signifi cant independent indicators compared to other clinical characteristics 
of the tumor [12, 13].
Proliferative activity Ki-67 marker is successfully used in researches and 
diagnosing of pathologies that are accompanied by changes in cell division activity. 
Its expression allows to determine the “hidden” proliferative potential of the tumor, to 
assess its malignancy and to divide the patients into groups with relatively favorable 
and unfavorable course of the disease [14, 15].
Expression of oncogene Human Epidermal growth factor Receptor 2 (HER2/neu) 
has been also studied enough in many tumors, particularly in mammary gland. HER2/
neu-positive status is oft en associated with a  high grade of malignancy, aff ection of 
lymph nodes and recurrence tendency and indicates that the tumor is resistant to 
chemotherapy [16]. Assessment of the ER, PR, proliferative activity of tumor cells and 
expression of oncogene HER-2/neu is important not only for determination of the 
biological characteristics of the tumor, but also for selection the therapy.
Th e object ive of this study is to determine the receptor status of PFTC tissue 
(ER, PR, Ki-67, HER2/neu).
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Materials and methods
Th e postoperative samples from 71 women with PFTC who were treated at regional 
oncologic dispensaries in the period from 2005 to 2015 were used for this research. 
Th e primary nature of the fallopian tube lesions was determined according to the 
criteria proposed by C.Y. Hu: 1) the macroexamination showed the tumor localization 
in the fallopian tube; 2) microexamination revealed aff ection of all mucous membrane 
layers; 3) when the fallopian tube wall is aff ected during the long period, the spreading 
of neoplasia occurs through the tube. Th e stages of the disease were determined 
according to FIGO staging system (2009). For morphological verifi cation of the 
diagnosis the paraffi  n blocks and histological sections, stained with hematoxylin and 
eosin, were used. Th e tumor histological type, tumor grades and degree of invasion 
were determined. In order to eliminate the impact of tumor histogenesis on the tumor 
cells immunophenotype, the criterion for inclusion in the study group of tumor was 
the presence of serous adenocarcinoma of the fallopian tube (n = 66) (the cases of 
mucinous, clear-cell adenocarcinoma and squamous cell carcinoma were excluded).
The 3–4 μm thick sections were prepared for immunohistochemical study, 
which were deparaffi  nized and dehydrated in xylene and ethanol with increasing 
concentrations according to standard procedure. Antigen retrieval was conducted 
in water bath at 97–98°C. Antigen- antibody interaction was visualized by detection 
system «Ultra Vision Quanto Detection System HRP DAB Chromogen» («Th ermo 
scientific», the USA), that included the blockage of endogenous peroxidase with 
hydrogen peroxide, blockage of nonspecific staining, using «Ultra V block», 
response intensifi er «Primary Antibody Amplifi er Quanto» and fi nal visualization 
by diaminobenzidine with nuclei staining with Mayer’s hematoxylin. To study the 
receptors for estrogen and progesterone the rabbit monoclonal antibodies (clone SP1 
— for determination of ER, clone SP2 — for PR) were used. Assessment of ER and 
PR expression was carried out according to D.C. Allred recommendations (1989), 
taking into account the area and intensity of the nuclei staining. Presence of nuclei 
with positive coloring was considered as steroid-positive reaction. Th e reaction was 
considered as negative with the amount of points 0–2, weak positive — 3–4 points, 
medium positive — 5–6 points and strong positive — 7–8 points. To assess the 
proliferative activity of tumor cells the rabbit monoclonal antibodies for Ki-67 protein 
(Clone SP6) were used. Tumor proliferative activity was assessed by the presence of 
positive stained nuclei of tumor cells. Proliferation index was determined by using 
the microscope «MICROmed», assessing the positive reaction in 1000 cells. Ki-67 
index was calculated as the ratio of specifi cally stained nuclei to all nuclei and were 
calculated in percentage: 0 points — negative reaction, 1 — weak reaction (the 
number of positive-stained cells (n) = 0–30%), 2 points — medium positive reaction 
(30 < n > 60%), 3 points — strong positive reaction (n > 60%). To determine the 
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HER-2/a neu oncoprotein the rabbit monoclonal antibodies (clone SP3) were used, 
taking into account the density and intensity of membrane staining. Assessment of 
HER2 expression was performed according to the rules DAKO Hertseptest and was 
classifi ed as negative (1+) or doubtful reaction (2+).
Statistical analysis was made in Microsoft  Excel 2010 with AtteStat 12.0.5. Th e 
assessment of the deflection probability of compared parameters was conducted 
according to Student‘s t-test (t). Th e correlation between studied parameters was assessed 
according to Pearson’s correlation (r). Th e results were considered as statistically reliable 
if the probability level was over 95% (r ≤ 0.05) when experimental r ≥ critical r.
Results
We determined that the women age aff ected by the fallopian tubes cancer ranges 
from 35 to 89 years (the mean age is 61.1 years). PFTC was most frequently observed 
(40.8%) in 60–69 years age group (Fig. 1).
Fig. 1. Patients with primary cancer of the fallopian tubes divided into age groups.
49 (69%) of patients were postmenopausal women. As a rule the neoplastic process 
is the one-sided process in 83.1% (n = 59) and in most cases aff ects the ampulla of 
the fallopian tube. Th e Stage I disease was observed in 24 patients (33.8%), II — in 
19 (26.8%), Stage III — in 28 (39.4%) (Fig. 2). Th e patients with Stage IV disease 
were not observed since such patients were treated only by palliative chemotherapy 
without surgery. 
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Fig. 2. Division of the patients with primary cancer of the fallopian tubes according to stages (FIGO, 2009).
All cases of serous adenocarcinoma were divided into 3 groups according 
to the differentiation grades: G1 — well — differentiated adenocarcinoma (low 
grade of malignancy) (n = 10), G2 — moderately — diff erentiated adenocarcinoma 
(intermediate grade of malignancy) (n = 23) and G3 — poorly — differentiated 
adenocarcinoma (high grade of malignancy) (n = 33).
Th e study of receptor status of serous cancer of the fallopian tubes showed that 
most of them were ER-positive (83.33%), in 41 cases (62.12%) of estrogen-positive 
neoplasia the expression of PR was determined. In 11 cases (16.67%) the negative 
profi le for both receptors was observed. Cases of PR positive status of tumor cells 
with ER absence were not found (Table 1). However the age does not infl uence the 
phenotype of the tumor (r = –0.09, p >0.05 for ER, r = –0.14, p >0.05 for PR). Th e 
study of the impact of diff erentiation grade on the tumor receptor phenotype showed 
the moderate negative correlation (r = –0.65, p = 1 for ER, r = –0.53, p = 1 for PR). 
Table 2 shows the indicators of ER and PR expression in PFTC tissue.
Table 1. Receptor phenotype of serous adenocarcinoma of the fallopian tubes.
ER+PR+ ER+PR– ER–PR–
n % n % n %
41 62.12 14 21.21 11 16.67
Table 2. ER and PR expression in PFTC tissues.
Receptor status Total points by D.C. Allred (1989) Number of ER cases Number of PR cases
Negative 0–2 11 25
Weak positive 3–4  9 12
Medium positive 5–6 31 24
Strong positive 7–8 15  5
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Analysis of the protein expression of Ki-67 in tumor cells of the fallopian tubes 
established that proliferative cells were found in all cases. The average index of 
proliferation was 55.02 ± 2.73% (12% to 95%). In 12 cases (18.18%) the reaction has 
weak positive level, in 18 cases (27.27%) has medium positive level — and in 36 cases 
(54.55%) has strong positive (Fig. 3).
Fig. 3. Serous adenocarcinoma of the fallopian tube. A — weak positive reaction Ki-67 < 30.0%, В — 
medium positive reaction — Ki-67 30–60%, С — strong positive reaction — Ki-67 > 60.0%. IHC study of 
Кі-67 expression. Magnifi cation × 160.
Th e dependence of tumor proliferative activity on the patient’s age was not found 
(r = 0.15, p >0.05). Th e tumor cells proliferation didn’t depend on diff erentiation type 
of serous adenocarcinomas (r = 0.13, p >0.05).
Ki-67 expression in women with Stage I was 54.65 ± 4.4%, with II — 53.94 ± 4.76%, 
with III — 55.96 ± 4.88%. No diff erence in Ki-67 expression of diff erent clinical groups 
of tumors (p >0.05) was found. Proliferative activity indicator in patients with cancer 
of the fallopian tube with metastases was 65.63 ± 4.98%, that is signifi cantly higher 
than that in patients without metastases (50.72 ± 3.08%), p = 0.006.
Assessment of HER-2/neu expression showed the doubtful reaction in 9.1% of 
cases (n = 6) that included moderate membrane staining — more than 10% of tumor 
cells and did not depend on the tumor diff erentiation grade (r = 0.06, p >0.05), stage 
of disease (r = 0.02, p >0.05) and presence of metastases (r = 0.06, p >0.05).
Discussion
Since 1866, when the PFTC was fi rstly described (K. Orthmann), it has been 
considered as a  rare, diffi  cultly diagnosed disease with a  bad prognosis. Stewart and 
others found that the incidence in women in the USA was 0.41 per 100 000 women 
from 1998 to 2003 [17]. Nowadays this type of neoplasia occurs more oft en in 
practical oncogynecology and is the primary source of serous ovarian and peritoneal 
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tumors [18, 19]. Th e problem of PFTC becomes more serious, although the causes 
and frequency of incidence, methods of diagnosis, prevention and treatment are not 
fully presented in modern medical literature. In patients anamnesis the infertility 
is rather oft en observed that is caused by amenorrhea or anovulatory cycles [20]. 
Repeated infl ammations of the uterine appendages are among factors that cause the 
neoplasia. Some cases of the coexistence of both the PFTC and tuberculous salpingitis 
are described [21]. In recent years, the theory of viral etiology in the development of 
fallopian tube cancer is considered, particularly the role of herpes virus type II, human 
papillomavirus and chlamydial infection [22]. Against of the chronic infl ammations 
in the tube, the pseudocarcinomatous hyperplasia can appear that is diffi  cult to 
diff erentiate from PFTC and these mistakes can lead to unnecessary radical surgery 
[23]. Currently it is proved that carcinoma of the fallopian tubes should be considered 
as part of the hereditary breast and ovarian cancer syndrome (HBOC) and may be 
connected with BRCA1 and BRCA2 gene mutations [3, 4, 24]. Th ere are some facts 
about women with BRCA1/2 mutations that prove that infundibulum parts of the 
fallopian tubes is an important place of cancer occurrence [25–27].
Preoperative diagnosis of PFTC is usually diffi  cult. Such symptoms as watery 
vaginal discharge, pain in the lower part of abdomen and extended mass in the pelvic 
on the side of the uterine are observed only in 15% of cases [28]. Th e most of patients 
with PFTC undergo the laparotomy with the presumed diagnosis of the ovarian 
cancer due to the presence of adnexal mass in pelvic. Th us, the PFTC should always 
be included in the diff erential diagnosis. High disposition for lymphatic metastasis 
is explained by abundant lymphatic network in the fallopian tubes. Considering 
this fact, there is an off er to remove the pelvic and paraaortic lymph nodes [29–31]. 
Th e results of this study demonstrate that mean age of patients is 61.1 years (from 
35 to 89 years), that corresponds to the previous studies [32], although sometimes 
PFTC is observed in young women (17–19 years) [28]. In 92.96% of cases the serous 
adenocarcinoma with various grades of diff erentiation was observed. Th e study of 
receptor status of serous cancer of the fallopian tubes showed that the majority of 
them are receptor — positive to both receptors or to ER-receptor (83.33%). Only in 
62.12% of cases the PR positive reaction was observed, that determine the tumor 
vulnerability to hormonal therapy. Th e cases of PR positive tumor cells with the 
absence of ER were not found, that prove the dependence of PR on the sensitivity 
of tumor cells to estradiol. Th us, the receptor profi le of fallopian tubes tumor did 
not depend on the age. When the malignancy increases the number of receptors for 
steroid hormones is reduced. Th e analysis of Ki-67 expression showed any correlation 
between indicators of proliferative activity, grades of diff erentiation and disease stages 
that indicates the independence of the speed of cell division in neoplasia, although 
in the majority of malignant tumors this indicator had direct link [33]. Proliferative 
activity in the tumors of the fallopian tubes with metastases was signifi cantly higher 
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than in tumors without metastases. It means that the study of Ki-67 expression is 
independent prognostic marker that should be considered in diagnosing the PFTC. 
Th is indicator has more signifi cant impact on the spreading of neoplasia through the 
body than its histological characteristics.
Th e analysis of oncoprotein HER-2/neu expression in tissue of PFTC showed the 
doubtful reaction in 9.1% of cases (n = 6) that signifi cantly diff ers from the studies of 
other authors who describe its high expression in more than 30% [34–36] but didn’t 
connect it with its presence and the survival rate of women. Th is may be caused by 
both the ethnic peculiarities of the patients and the tumor sensitivity to diff erent 
antibodies (depends on the producer). Th is research demonstrates that fallopian tubes 
cancer is mainly HER-2/neu negative and we cannot recommend this oncoprotein in 
routine examinations of such patients.
Conclusions
Fallopian tubes pathologies require proper attention of both pathologists and 
gynecologists. Th e primary cancer of the fallopian tubes more commonly aff ect 
the  postmenopausal women, aged 60–69 years, mainly in early stages of the disease 
 ( I–II) (60.8%) and in most cases was represented as serous adenocarcinoma (92.96%). 
It was determined that most of them are receptor-positive for both steroid receptors 
(ER — 83.33%, PR — 62.12%). But the receptor profi le of the tumor of the fallopian 
tubes did not depend on the age. When the tumor diff erentiation grade becomes lower 
the number of receptors for steroid hormones also reduces. High level of proliferative 
activity is typical for this type of neoplasia. Th is activity is not depend on the age, 
stage of the disease and tumor diff erentiation grade. But it indicates the severity 
course of the disease that infl uences the spreading of neoplasia through the body. 
Considering this fact the Ki-67 expression is independent marker for N-status and 
helps to determine the patients who are in the “risk” group. HER-2/neu expression 
is not typical for primary cancer of the fallopian tubes, taking into account almost 
complete lack of it (only 9% — doubtful reaction) in tumor tissue.
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